how common is gastroparesis with tirzepatide vs. Side Effects: What to Know GLP-1 and Gastroparesis: Clinical Safety

The future of the diabetes clinical trials market will be driven by biologics, gene-based therapies, digital therapeutics, wearable monitoring technologies, and decentralised clinical trials

What are the risks and warnings when taking Wegovy

How does it decrease muscle damage

For type 2 diabetes, the typical starting dose is 0.25 mg once weekly, which may be increased to 0.5 mg after four weeks

These include nausea, vomiting, stomach pain, stomach cramps, and diarrhea

Patient Eligibility and Contraindications FDA approval requires BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)